Wash. Woman Claims Long-Term Gabapentin Use Caused Cognitive Problems
A Washington woman sued Pfizer, alleging long-term use of gabapentin caused cognitive issues. The plaintiff claims Pfizer knew of risks but concealed them. The case was filed in U.S. District Court for the Eastern District of Washington.
How this was made

The 30-second read
Why it matters
If the claims gain traction, they can increase perceived litigation exposure and potentially trigger additional scrutiny of safety communications, though the article provides no settlement, damages, or regulatory action.
Market read
This is a company-specific legal overhang item for Pfizer, but without quantified financial impact or a procedural milestone, it is unlikely to drive a major repricing by itself.
What to watch
Traders may overreact to allegations; the market impact typically depends on whether similar cases are already priced in, the procedural posture (dismissal/MDL), and any contemporaneous FDA label or safety-communication updates.
Background
The piece describes a Washington state plaintiff suing Pfizer in federal court, alleging gabapentin’s long-term use caused cognitive effects and that Pfizer knew of the risks for decades.
Ticker impact
Pfizer is named as the defendant in a lawsuit alleging long-term gabapentin use caused cognitive problems and that Pfizer concealed risks from doctors and the public.
Likely downside pressure as markets price in higher litigation and regulatory scrutiny risk tied to gabapentin.
The article is a first-report style lawsuit filing naming Pfizer, which can drive incremental risk premium even without an announced settlement or quantified damages.
Market effects
Adds to broader scrutiny of gabapentinoid safety communications and product-liability risk across large pharma.
Primarily US-focused legal/regulatory overhang for Pfizer.
Moderate, as gabapentin safety and labeling disputes can resonate internationally even if the filing is US-based.
Counterpoint
A single pro se complaint may not materially change Pfizer’s near-term fundamentals unless it leads to major discovery, consolidated MDL movement, or a quantified settlement.
Key entities
- companyPfizer Inc.
Named defendant accused of concealing gabapentin cognitive-risk information.
- personAnne McBride
Plaintiff alleging cognitive problems after long-term gabapentin use.
- courtU.S. District Court for the Eastern District of Washington
Venue where the complaint was filed.




